---
title: "Orphazyme A/S Unsponsored ADR (ORPHY.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ORPHY.US.md"
symbol: "ORPHY.US"
name: "Orphazyme A/S Unsponsored ADR"
---

# Orphazyme A/S Unsponsored ADR (ORPHY.US)

## Company Profile

Orphazyme A/S 是一家生物制藥公司，致力于為患有危及生命和虛弱的罕見疾病的患者開發治療方法。它提供了 Arimoclomol 程序和分子實體程序。該公司由 Anders Morkeberg Hinsby、Marja Jaattela、Martin Rahbek Kornum 和 Thomas Kirkegaard Jensen 于 2009 年創立，總部設在丹麥哥本哈根。

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/ORPHY.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ORPHY.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ORPHY.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.